Nociceptin Receptor Research Report: Competitor, Under Development Projects, Mergers and Acquisition, Discontinued Projects and more
Nociceptin Receptor – Pipeline Review, H1 2018, outlays comprehensive information on the Nociceptin Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and m
(EMAILWIRE.COM, April 03, 2018 ) Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) – Nociceptin receptor also known as the nociceptin or orphanin FQ receptor or kappa-type-3 opioid receptor is a protein encoded by the OPRL1 (opioid receptor-like 1) gene. NOP receptors are located both pre- and post-synaptically in various areas of CNS. The nociceptin receptor (NOP) and its endogenous ligand, nociceptin are involved in biological functions, such as pain, anxiety, learning, and memory.
Report Source: https://www.themarketreports.com/report/nociceptin-receptor-kappa-type-3-opioid-receptor-or-kor3-or-orphanin-fq-receptor-or-oprl1-pipeline-review-h1-2018
Scope
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Nociceptin Receptor targeted therapeutics and enlists all their major and minor projects
• The report assesses Nociceptin Receptor targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Nociceptin Receptor targeted therapeutics
Purchase this report at: https://www.themarketreports.com/report/buy-now/987791
The universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular and Immunology which include indications Dyskinesia, Substance (Drug) Abuse, Chronic Pain, Neuropathic Pain, Pain, Acute Pain, Alcohol Addiction, Bladder Pain, Cancer Pain, Diabetic Neuropathic Pain, Drug Addiction, Hypersensitivity, Inflammatory Pain, Low Back Pain, Major Depressive Disorder, Osteoarthritis Pain, Parkinson's Disease, Post-Traumatic Stress Disorder (PTSD), Pulmonary Arterial Hypertension and Systolic Hypertension.
Got a question; ask us at: https://www.themarketreports.com/report/ask-your-query/987791
Report Source: https://www.themarketreports.com/report/nociceptin-receptor-kappa-type-3-opioid-receptor-or-kor3-or-orphanin-fq-receptor-or-oprl1-pipeline-review-h1-2018
Scope
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Nociceptin Receptor targeted therapeutics and enlists all their major and minor projects
• The report assesses Nociceptin Receptor targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Nociceptin Receptor targeted therapeutics
Purchase this report at: https://www.themarketreports.com/report/buy-now/987791
The universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular and Immunology which include indications Dyskinesia, Substance (Drug) Abuse, Chronic Pain, Neuropathic Pain, Pain, Acute Pain, Alcohol Addiction, Bladder Pain, Cancer Pain, Diabetic Neuropathic Pain, Drug Addiction, Hypersensitivity, Inflammatory Pain, Low Back Pain, Major Depressive Disorder, Osteoarthritis Pain, Parkinson's Disease, Post-Traumatic Stress Disorder (PTSD), Pulmonary Arterial Hypertension and Systolic Hypertension.
Got a question; ask us at: https://www.themarketreports.com/report/ask-your-query/987791
Contact Information:
The Market Reports
Shirish Gupta
Tel: +1-631-407-1315
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
The Market Reports
Shirish Gupta
Tel: +1-631-407-1315
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results